EpiSign Launches METRIC 5-base, Enabling Comprehensive Episignature Analysis Across Genome-Sequencing Platforms
New software extends automated analysis of more than 300 episignature disorders beyond methylation microarrays to Illumina 5-base, PacBio HiFi and Oxford Nanopore sequencing data LONDON, ON, Sept. 30, 2026 /PRNewswire/ -- EpiSign Inc. today announced the launch of EpiSign METRIC 5-base,...
Covered in this story
What has happened since
- Illumina is down 2.1% since this was published, 20 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $ILMN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Illumina →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.